Favrille Announces Execution of Non-binding Term Sheet for a Merger Transaction
SAN DIEGO, Oct. 24 /PRNewswire-FirstCall/ -- Favrille, Inc. (OTC Bulletin Board: FVRL) announced today that it has entered into a non-binding term sheet for a reverse merger whereby Favrille would acquire all of the capital stock of a private company, MyMedicalRecords.com, Inc. ("MMR"), in a s...Boston Scientific Provides Comments Reinforcing Strength of Its Balance Sheet
Company moves up Q3 earnings release date NATICK, Mass., Oct. 14 /PRNewswire-FirstCall/ -- Boston Scientific Corporation (NYSE: BSX ) today provided the following comments reinforcing the strength of its balance sheet: The volatility of the financial markets and the Company's...Musicnotes strikes deal to distribute Sony/ATV sheet music
Madison, Wis. - Guitarists and other musicians will find a greater selection of their favorite sheet music in the Capital City, thanks to a deal struck by a local online store. Madison-based Musicnotes Inc. , an Internet-based sheet music store, reached an agreement Friday to distribute the ...Novavax Reports Second Quarter 2009 Financial Results
...advance its vaccine pipeline, improved its balance sheet by raising additional capital and retiring 100% of...of this year. Improved the company's balance sheet by retiring 100% of its $22.0 million of outstandi...ATM program. Today, Novavax has a healthy balance sheet with no long term debt and cash and short-term inv...NeurogesX Reports Second Quarter 2009 Results
...CFO, commented, "During the second quarter 2009 we strengthened our balance sheet substantially with upfront payments of approximately $48.8 million due from... ======= ======= (1) The balance sheet at December 31, 2008, has been derived from the audited consolidate...Microbix Sales Grow 22% For Nine Months
...any commercial players. The Microbix technology has the potential to provide a new entry company with full IP exclusivity. As previously reported term sheet agreements have already been signed with artificial insemination companies worldwide." Urokinase The Company acquired all Urokinase assets f...GenVec Reports Second Quarter 2009 Financial Results
... 77,073 ====== ====== ====== ====== GenVec, Inc. Selected Balance sheet Information (in thousands) June 30, December 31, ...SEQUENOM Reports Second Quarter 2009 Financial Results and Highlights
...(0.33) $(0.21) $(0.62) $(0.40) ====== ====== ====== ====== Consolidated Balance sheet Information June 30, December 31, 2009 ...Telik Announces Second Quarter 2009 Financial Results
... 53,185 53,335 53,088 ====== ====== ====== ====== Selected Balance sheet Data (In thousands) (Unaudited) ...Repligen Reports First Quarter Fiscal Year 2010 Financial Results
...luted 30,742,212 31,585,112 ========== ========== Balance sheet Data: June 30, 2009 March 31, 2009 ------------- -------------- Cash, cash equival...Keryx Biopharmaceuticals, Inc. Announces Second Quarter 2009 Financial Results
... 47,855,425 44,095,873 47,854,664 43,906,974 Diluted 48,189,552 44,095,873 48,149,600 43,906,974 Balance sheet Information: June 30, 2009 December 31, 2008* ------------- ...PDI Reports 2009 Second Quarter Financial Results
... - 12,289 Gross profit % 22.7% 45.0% NM 0.0% 19.6% NM - Not Meaningful Selected Balance sheet Data (Unaudited) (in thousands) June 30, December 31, ...Cord Blood America Retires $2.53M Obligation
...d that decreasing debt would be one of our significant items to focus on in 2009," said Mr. Schissler. "Eliminating debt makes our financial balance sheet stronger and makes Cord Blood America a better investment. We are very pleased with this development." About Cord Blood America Cord Blo...Genomic Health Announces Second Quarter 2009 Financial Results and Business Progress
...' equity $83,568 $86,689 ======= ======= The condensed consolidated balance sheet at December 31, 2008 has been derived from the audited consolidated financial statements at that date included in the Company's Form 10-K for ...CuraGen Reports Second Quarter 2009 Financial Results
... 57,051 56,736 57,027 56,629 ====== ====== ====== ====== SELECTED BALANCE sheet INFORMATION June 30, December 31, 2009 2008 ...Sangamo BioSciences Reports Second Quarter 2009 Financial Results
...re 41,123 40,858 41,094 40,673 ====== ====== ====== ====== SELECTED BALANCE sheet DATA: June 30, 2009 December 31, 2008 ------------- ----...Neurocrine Biosciences Reports Second Quarter 2009 Results
...onally, other non-personnel cost savings have resulted in six month over six month savings of approximately $1.2 million. The Company's balance sheet on June 30, 2009 reflected total assets of $86.9 million, including cash and investments of $74.0 million compared with balances at December 31, 2008 ...Sunesis Reports Financial Results for the Second Quarter 2009
... $9,785,803 $12,783,829 ========== =========== Note 1: The condensed consolidated balance sheet as of December 31, 2008 has been derived from the audited financial statements as of that date included in the Company's Annual Report on Form...Cynosure Reports Second Quarter 2009 Financial Results
... 12,711 12,513 12,706 12,492 ====== ====== ====== ====== Condensed Consolidated Balance sheet (Unaudited) ------------------------------------------------ (In thousands) June 30, ...NeoGenomics Reports Second Quarter 2009 Results
...p://www.neogenomics.org . For more news and information on NeoGenomics, please visit www.IRGnews.com/coi/NGNM where you can find a fact sheet on the company, investor presentations, and more. Interested parties can also access additional investor relations material, including an investment ...Cardium Regains Listing Compliance with NYSE Amex
... its position and other qualifications. "We are very pleased that the NYSE Amex has recognized the substantial improvement to Cardium's balance sheet and operational savings associated with our InnerCool transaction with Royal Philips Electronics," stated Christopher J. Reinhard, Chairman and Chief ...UCR scientists manipulate ripples in graphene, enabling strain-based graphene electronics
...replace silicon as the main electronic material, graphene is a single layer of graphite. Even though graphite has been studied for decades, the single sheet first was isolated experimentally only in 2004. Graphene's structure is a two-dimensional honeycomb lattice of carbon atoms. Structurally, it is relat...Neogen Reports 16% Increase in Revenues
... Net income increase vs. FY 2008 7.6% 14.7% NEOGEN CORPORATION UNAUDITED SUMMARIZED CONSOLIDATED BALANCE sheet DATA (In thousands) May 31 May 31 2009 20...Cardium's InnerCool Therapies Business to Be Acquired By Royal Philips Electronics
...dical investment portfolio. With a substantially reduced cost structure, the proceeds from this transaction will be used to enhance Cardium's balance sheet and for working capital to support the further development of Cardium's biomedical investment portfolio and product development pipeline, particularly...Gerresheimer Holds its own in Difficult Environment
...urther course of the financial year are difficult. Gerresheimer AG does not however assume any short-term recovery of these markets. The sound balance sheet and long term financÂing structure as well as a good operating performance will enable Gerresheimer to continue the growth strategy in the pharma &am...Santaris Pharma - Interim Report for the Period 1 January to 30 June 2009
...K (4,0 EUR). The Net Financial Income in the first half of 2009 was 9,6m DKK (1,3m EUR) compared to 6,3m DKK (0,8m EUR) in 2008. Balance sheet and Cash Flow As at June 30 2009, the Company had total assets of 234,6m DKK (31,5m EUR) of which the Cash & Cash Equivalents amounted to 1...Material world: Graphene's versatility promises new applications
...f graphene are shed whenever a pencil line is drawn, though producing a 2-D sheet of the material has proven trickier. Graphene is remarkable in terms of thinness and resiliency. A one-atom thick graphene sheet sufficient in size to cover a football field, would weigh less than a gram....Verenium Completes Amendment to 8% Senior Convertible Notes
...de in shares of our common stock. "The amendments that are effective today are an important first step towards creating a balance sheet for Verenium that can support the capital needs of the Company going forward," said James E. Levine, Chief Financial Officer at Verenium. The mat...Kewaunee Scientific Reports Record Results Net Earnings for Year Increase 36%, Sales Increase 16%
...the prior year, while sales from international operations were $1,874,000, down from sales of $4,101,000 in the prior year. The Company's balance sheet remains strong. Working capital increased to $18.9 million at April 30, 2009, up from $15.9 million at the end of the prior year. Cash on hand at the...Nanobiotech Center Wins $2.5 Million, 4-Year Grant
...gram at the Biotechnology Center. Nanotechnology involves structures between one and 100 nanometers in size--roughly 10,000 times thinner than a sheet of paper. Companies in North Carolina are already working on nanoparticles that treat disease by carrying new genes to certain cells, and sunlight-pow...Helix BioPharma Announces Q3 2009 Financial Results and Provides Product Development Update
...ill be available. The Company's unaudited interim consolidated balance sheet as at April 30, 2009, and audited consolidated balance sheet as at July 31, 2008, are summarized below: Consolidated Balance S...Biologist discovers pink-winged moth in Chiricahua Mountains
... Walsh discovered L. leeae while collecting one evening at Onion Saddle, at about 7,700 feet in the Chiricahuas. Collecting involves illuminating a sheet with mercury vapor lamps. Moths are attracted by the lights and will land on the sheet. "This large moth flew in and we didn't think much of it bec...Repligen Reports Fourth Quarter and Fiscal Year 2009 Financial Results
... 30,697,818 31,064,483 30,957,957 30,834,491 Diluted 30,961,807 31,064,483 31,290,233 31,320,997 Balance sheet Data: March 31, 2009 March 31, 2008 Cash, cash equivalents and marketable securities* $63,960,564 ...Pharmaxis Announces Placement of $47 Million and Share Purchase Plan
... million through a placement to Australian and international institutions and professional investors. The placement strengthens the company's balance sheet as Pharmaxis moves toward the European and U.S. commercial launch of its product Bronchitol for cystic fibrosis. Pharmaxis will issue 20 millio...